|
|
|
|
Document Preview Agreement |
||||
|
|
||||
|
Click "Add to Cart" button to purchase document. |
||||
|
|
||||
|
Title: |
Agreement |
|||
|
Entities: |
||||
|
Date: |
2004 |
|||
|
Size: |
Preview shows 20KB of 119KB total |
|||
|
Price: |
$50 |
|||
|
ID: |
#283575 |
|||
|
|
||||
|
||||
|
|
||||
|
Start of Preview |
||||
Exhibit 10.7
Confidential Materials omitted and filed separately with the
AGREEMENT
THIS AGREEMENT is made effective as of the 16th day of October, 2003, between IDEXX Operations, Inc., a Delaware corporation whose principal place of business is at 6100 East Shelby Drive, Memphis, Tennessee 38141, U.S.A. (?IDEXX?) and Ortho-Clinical Diagnostics, Inc., a New York corporation with offices at 100 Indigo Creek Drive, Rochester, New York, U.S.A. (?OCD?).
WHEREAS, OCD has been a supplier of analyzers for human applications and dry slides, and IDEXX has been a supplier of analyzers for animal applications;
WHEREAS, OCD and IDEXX Laboratories, Inc. (?IDEXX Parent?), the parent company of IDEXX, entered into a supply agreement effective as of January 1, 1999 (the ?Prior US Agreement?) with respect to the supply of VITROS slides in the United States and Asia for use on the VETTEST Analyzer (as defined below); and
WHEREAS, OCD and IDEXX Europe B.V. (?IDEXX BV?) entered into a supply agreement effective as of January 1, 1999 with respect to the supply of VITROS slides in Europe for use on the VETTEST Analyzer (the ?Prior Europe Agreement?), and intend to amend and restate the Prior Europe Agreement shortly after the date hereof to make certain modifications thereto; and
WHEREAS, OCD, IDEXX Parent and IDEXX BV entered into that certain Operations Agreement effective as of January 1, 1999 (the ?Operations Agreement?); and
WHEREAS, OCD, IDEXX Parent and IDEXX BV entered into that certain Amendment, Release and Settlement Agreement dated as of September 12, 2002 (the ?Settlement Agreement?) for purposes of, among other things, amending the Prior US Agreement, the Prior Europe Agreement and the Operations Agreement and resolving certain disputes between the parties; and
WHEREAS, OCD and IDEXX desire to expand their relationship in order to create a New Analyzer (as defined below) for animal applications, which will expand the sales of OCD?s dry slides and IDEXX?s analyzers, and to make IDEXX products more competitive;
WHEREAS, OCD and IDEXX through this Agreement desire to combine certain of their respective skills and intellectual property and to invest significant capital to create the New Analyzer and related panel holder design, which is expected to provide a better product offering to customers;
WHEREAS, this Agreement will ensure IDEXX of a continuing supply of Dry Slides necessary for its continued sale of analyzers, including the New Analyzer.
WHEREAS, OCD and IDEXX now desire to enter into new arrangements for the supply and development of diagnostic slides and analyzers, the terms and conditions of which are documented herein;
NOW THEREFORE, the parties hereby agree as follows:
| 1. | DEFINITIONS |
In this Agreement the following expressions shall have the meaning set opposite them.
| ?Agreements? | This Agreement and the Europe Agreement. | |
| ?Analyzers? | The VETTEST Analyzer and the New Analzyer. | |
| ?Commencement Date? | October 16, 2003. | |
| ?Dry Slide? | A chemical composition, comprising a layered, coated dry film, specifically formulated to analyze for a body constituent, which composition is immediately hydrated by any undiluted bodily fluid, including without limitation a VITROS slide. For avoidance of doubt, the term ?Dry Slide? shall not include any assay based on immunomagnetic particle technology or any assay for which the analyte is DNA or RNA. | |
| ?Effective Rebate Rate? | For any year, the weighted average percentage reduction in the purchase price of any slides purchased in such year that IDEXX is entitled to receive pursuant to Section 7.03 hereunder. The calculation of the Effective Rebate Rate is illustrated in Schedule 7. | |
| ?Europe Agreement? | The Prior Europe Agreement, until such time as it is amended and restated as contemplated by the preamble; from and after such time, the ?Europe Agreement? shall mean the Prior Europe Agreement as so amended and restated. | |
| ?Exclusivity Territory? | The United States of America and its possessions (including Puerto Rico), Canada, Australia, New Zealand, Japan, India, South Korea and Taiwan. |
2
| ?Existing Special [**] Slides? | VETTEST slides that have been [**], as of the date of this Agreement, pursuant to Section 4 of the Operations Agreement. | |
| ?IDEXX BV? | IDEXX Europe B.V., a Netherlands corporation. | |
| ?New Analyzer? | A new chemistry analyzer that uses OCD Dry Slides for veterinary applications, as contemplated by Article 3 of this Agreement, and any updates or modifications to such analyzer. | |
| ?New Chemistry Slides? | As defined in Section 5.06. | |
| ?New Slide/Panel Design? | A new slide format for VETTEST slides to be used in conjunction with the New Analyzer, as well as a panel holder for such slides, as contemplated by Article 3, and any updates or modifications to such design. | |
| ?New Slides? | VETTEST slides that are formatted and packaged in accordance with the New Slide/Panel Design, as contemplated by Article 3. | |
| ?New Special [**] Slides? | VETTEST slides that have been [**] pursuant to Section 7.04 of this Agreement. | |
| ?PANELS/PROFILES? | Packages of VETTEST slides for VETTEST Analyzers consisting of two or more sets of slides of specified chemistries. The initial PANEL and the initial PROFILES shall consist of the slides set forth on Schedule 3 attached hereto, with any changes or additional PANELS/PROFILES to be mutually agreed upon by the parties as specified in Schedule 3. | |
| ?Prime Rate? | For any day in any calendar month, the prime rate of interest as published in the Wall Street Journal on the last business day of the immediately preceding month. | |
| ?Proportionate Share? | The percentage obtained by dividing (i) the number of VETTEST slides purchased by IDEXX in a given period, by (ii) the total number of VETTEST slides |
3
| purchased by IDEXX and its affiliates during such period. | ||
| ?Special [**] Slides? | Existing Special [**] Slides and New Special [**] Slides. | |
| ?Term? | As defined in Section 18.01. | |
| ?Territory? | Worldwide, except the European Union, Africa, and the countries listed on Schedule 10 attached hereto. | |
| ?VETTEST Analyzer? | The analyzer currently marketed as the VETTEST VT 8008 analyzer and any updates or modifications to such analyzer. | |
| ?VETTEST slides? | Dry Slides currently manufactured by OCD, specially designed, bar coded, labeled, and/or packaged for one or more of the Analyzers in accordance with the terms of this Agreement and supplied by OCD in accordance with the terms and conditions of this Agreement. | |
| ?VETTEST tips? | Metering tips sourced by OCD for use with the VETTEST Analyzer, specially packaged and supplied to IDEXX in accordance with the terms of this Agreement. | |
| ?VITROS slides? | The Dry Slides currently manufactured by OCD for use in any current VITROS analyzer, including without limitation the DT60. |
All references to currency in this Agreement shall mean U.S. Dollars unless otherwise specifically indicated.
| 2. | EFFECTIVE DATE OF AGREEMENT | |
| 2.01 This Agreement shall become effective upon the Commencement Date. This Agreement shall apply solely within the Territory; except that Sections 3.04, 3.05 and 3.06 shall apply worldwide. | ||
| 3. | DEVELOPMENT OF NEW ANALYZER AND NEW SLIDE/PANEL DESIGN |
| 3.01 | IDEXX and its affiliates shall, at their expense, and with cooperation from OCD as set forth below, devote chemistry instrument development resources to the development and launch of the New Analyzer. IDEXX and its affiliates shall use |
4
| commercially reasonable efforts to achieve commercial launch of such analyzer within the United States within [**] years of the Commencement Date. IDEXX shall have control and management of New Analyzer development, and sole approval of New Analyzer specifications. | |||
| 3.02 | IDEXX and its affiliates shall, at their expense, design, develop and validate the New Slide/Panel Design, together with the injection molding tooling for the panel holder and associated label content and art work. IDEXX shall have control and management of New Slide/Panel Design development, and sole approval of New Slide/Panel Design specifications. | ||
| 3.03 |
|
End of Preview |
Home Intelligence Services Subscriptions News About Us